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Background.Tilteddiscsyndrome(TDS)isacongenitalanomalycharacterizedby“tilting”oftheopticdisctipycallyassociatedwith
myopic astigmatism, visual ﬁeld defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications
such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown.
Methods. One interventional case report is hereby described. A patient aﬀected by macular serous neuroretinal detachment-
complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and ﬂuorescein
angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25mg/0.05mL)
were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence
of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort.
Conclusion. Clinical evidence of this brief interventional case report indicates that one patient aﬀected by recent serous macular
detachment-complicated TDS did not beneﬁt from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual
acuity remained stable over a total observation period of 6 months.
1.Introduction
Tilted disc syndrome (TDS) is a congenital anomaly char-
acterized by a nasal-to-temporal “tilting” of the optic disc
associated with inferonasal crescent, myopia, myopic astig-
matism, visual ﬁeld defect, inferior staphyloma, and retinal
pigment epithelium (RPE) atrophy [1–4]. The syndrome is
associated with complications such as macular serous neu-
roretinal detachment [5, 6] or choroidal neovascularization
[7].
2. Matherials andMethods
Thiscasereportisabouta70-year-oldwomanwhopresented
with loss of visual acuity (VA) in the left eye, with metamor-
phopsia dating from a few days before.
The patient’s eyes were carefully examined including
best-corrected VA (BCVA) testing (Snellen equivalent),
optical coherence tomography (Stratus OCT, Carl Zeiss,
Dublin, CA, USA) and ﬂuorescein angiography (Topcon
Corp., Japan).
After obtaining informed consent, oﬀ-label beva-
cizumab (Avastin, 1.25mg/0.05mL) was injected intravit-
really twice at monthly interval, in the operating theatre
through a 30 gauge needle at 3.5 to 4mm of inferotemporal
limbus.
3. Results
When referred to our attention patient’s best corrected
VA was 20/100 (refraction error: +0.50–3@180D). Fundus
examination showed tilted insertion of the optic disk
with atrophic peripapillary changes associated with inferior
staphyloma. Fluorescein angiography (FA) disclosed a foveal
diﬀuse RPE atrophy/distrophy and a small hyperﬂuorescent2 Journal of Ophthalmology
After 2 intravitreal monthly avastin
(f) (g) (h)
(d) (c) (b) (a)
(e)
Figure 1:(a),(b),(c),(d):imagingbeforeintravitrealbevacizumab.(e),(f),(g),(h):imagingafterintravitrealbevacizumab.Redfreepicture
(a) shows tilting of optic disk with inferior staphyloma. RPE pigmentary changes are evident along the staphyloma area. In early mid-phases
of ﬂuorescein angiography (b, c) an hyperﬂuorescent dot (yellow arrow) becomes evident over a background of diﬀuse oblique-oriented
RPE atrophy that typically overlies the staphyloma. At 5-minutes late phase (d) leaking point intensity dissolves into a diﬀuse vanishing
hyperﬂuorescence. After treatment the primitive leaking dot (red arrow) is not detectable in early (f), middle (g), or late phases (h) of
ﬂuorangiography.
After 2 intravitreal monthly avastin
(f) (g) (h)
(d) (c) (b) (a)
(e)
Horizontal scansion
Horizontal scansion
Vertical scansion
Vertical scansion
Figure 2:(a),(b),(c),and(d):imagingbeforeintravitrealbevacizumab.(e),(f),(g),and(h):imagingafterintravitrealbevacizumab.(a),(c),
(e), and (g): infrared imaging shows macular position of OCT scanner at infra-red picture. Serous neuroretinal detachment is well evident
in both vertical and horizontal scansion, before (b, d) and after bevacizumab injection (f, h). Presumed focal defect in RPE corresponding
to the active leaking point is indicated by the pink arrow. Amount of serous ﬂuid (white arrow) leaking from underling RPE-choriocapillary
layer is tomographically unchanged.
spot with little leakagein the middle-late phases of the exam-
ination (yellow arrow, Figure 1, top stripe), corresponding to
the focal RPE leaking point.
OCT evidenced a foveal serous neuroretinal detach-
ment (Figure 2, top stripe) in both vertical and horizontal
scansion.
At scheduled visit, one month after second injection,
complete imaging was repeated.
OCT depicted persistence of neuroretinal detachment
(Figure 2, bottom stripe) whilst FA (Figure 1,b o t t o m
stripe) showed disappearance of previous hyperﬂuorescent
spot. Entity, distribution, and dimension of RPE atro-
phy/dystrophyareaunchangedandprimitiveleakingdotwas
completely angiographically silent.
Best-corrected VA remained 20/100 and metamorphop-
sia were stable. The patient refused additional treatments.Journal of Ophthalmology 3
Six months after treatment, the macular detachment
remained per OCT.
4. Discussion
Subretinal leakage in myopic eyes with TDS remains a poorly
recognized disease entity and a relatively young disease, as
ﬁrst reports were published in 1998 [5]. It is extimated to
occur in 41% of TDS cases [7]. Although OCT technology
is a useful aid in diagnosis and followup, the natural
history and pathophysiology of serous macular detachment
are not well understood. Anti-VEGF therapy with intrav-
itreal injection of ranibizumab and pegaptanib has been
approved for neovascular age-related macular degeneration.
Additionally, bevacizumab is utilized worldwide as an oﬀ-
label therapeutic option in many other retinal disease such
as pathologic myopia and central serous chorioretinopathy
(CSC) [8], due to the low cost of the drug, with encouraging
results.
CSC is a well-characterized disease with typical ﬁndings
including subretinal leakage similar to aspects of TDS-
associated serous macular detachment. Retinal pigment
epithelium dysfunction has been suggested as a possible
primitive step in both pathological conditions. Intravitreal
bevacizumab has been reported in 5 patients as a new
option in the treatment of central serous chorioretinopa-
thy [8] and was associated with visual improvement
and reduced neurosensory detachment without adverse
events.
In our patient, laser photocoagulation of the leakage was
not possible in our opinion because of its foveal position,
so we decided to employ 1.25mg intravitreal avastin as
oﬀ-label treatment. Following bevacizumab, repeated FA
documented the disappearance of the early leaking point
(red arrow, Figure 1, bottom stripe), but the serous ﬂuid
did not reduce on OCT (Figure 2, bottom stripe). This is
diﬃcult to explain, but some discordance is known between
FA and OCT imaging [9]. In our patient, it is noteworthy
that persistent neuroretinal detachment was more strongly
tied to functional recovery than angiographic pinpoint
activity.
As the prognosis of untreated TDS-related macular
serous detachment is not well deﬁned, we can postulate that
it can waxand wane similarly to chronic CSC or perhaps that
intravitreal avastin may have some inﬂuence on closing the
leaking dot.
I tm a yh a v eb e e ni l l u s t r a t i v et oi n v e s t i g a t et h ee ﬀects of
further intravitreal treatments, but the patient experienced
no BCVA improvement and declined additional therapy;
macular serous detachment persisted at 6-month followup.
In conclusion, the ideal treatment for macular serous
detachment in TDS remains unknown. In this single case,
Avastin as employed did not appear to inﬂuence BCVA
outcome.
More data about Avastin and other VEGF inhibiters
in the treatment of serous macular detachment-compli-
cated TDS are required to further deﬁne prognosis and
eﬃcacy.
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